All Hail Supply Chain Finance — The New King of Spend Management Posted At : June 26, 2008 1:06 PM Related Categories: Spend Management In probably over a dozen speeches this spring, I talked about how "pay" was becoming just as — if not more — important than "procure" in the procure-to-pay equation. It's good to see that others are validating the rise of the payment side of procurement. According to this article in Finance Week, supply chain finance, a "pay" element, is on the rise. Anhttp://www.spendmatters.com/index.cfm/2008...

Don Imus, whose oh-so-charming "nappy headed hos" comment last year got him fired (and rehired) from his radio show, has once again proven him to be a grade-A asshole and racist. During a conversation about [Dallas Cowboys cornerback Adam] Jones' run-ins with the law, Imus asked, "What color is he?" Sports announcer Warner Wolf said Jones â€" formerly known as Pacman â€" is "African-American." Imus responded: "There you go. Now we know." Imus is trying to defend his comments by saying he was makinhttp://feministing.com/archives/009455.htm...

The laying on of hands, also known as energy healing, energy therapy, bio-energy therapy, bio-field therapy and energy work, promotes healing by enhancing the energy flow and correcting disturbances in the human aura that surrounds the body. This improvement of the flow of aura's energy supports the self-healing capacity of the body. The laying on of hands is an old healing modality that is making its way back into our lives in a revival of ancient understandings. All around the world people ihttp://watersana.typepad.com/watersana/200...

Three weeks after the FDA allowed Wyeth to begin marketing what the drugmaker calls a reformulated version of its heartworm med on a restricted basis, a pair of dogged Congressional reps want the agency to justify its decision. ProHeart 6, you may recall, was yanked four years ago after being linked to an unusually high rate of deaths and serious side effects. The episode spoke poorly of the FDA, though. In 2003, an FDA vet examined a growing number of adverse reactions, prompting the withdrawhttp://www.pharmalot.com/2008/06/congress-...